Senores Pharmaceuticals Limited has made a regulatory disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the successful completion of a United States Food and Drug Administration (USFDA) inspection.
The inspection was conducted at the manufacturing facility of Apnar Pharma Private Limited, a subsidiary company of Senores Pharmaceuticals Limited. The facility is located in Vadodara, Gujarat.
The inspection period was from Monday, September 7, 2026, through Friday, September 11, 2026. The outcome of the inspection was successful with only one minor procedural observation and no GMP (Good Manufacturing Practice)-related observations.
The subsidiary company, Apnar Pharma Private Limited, will submit its response to the USFDA within the stipulated timeframe as required.
The disclosure was signed by Shilpa Sharma, Company Secretary and Compliance Officer (ICSI Membership No.: A34516) of Senores Pharmaceuticals Limited, whose registered office is at 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India.